Quanterix Corporation (QTRX) CEO Departs; Jim Gute Named Interim CEO

Quanterix Corporation's CEO Everett Cunningham resigned, with Chief Commercial Officer Jim Gute appointed interim CEO. The company reaffirmed its 2026 outlook.

Original reporting
Published Nov 18, 2026, 1:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 1:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Quanterix Corporation (QTRX) CEO Departs; Jim Gute Named Interim CEO — source image
Decision brief

The 30-second read

$QTRXNeutralMed
01

Why it matters

The market may reprice near-term execution risk and governance stability, but the company’s reaffirmation of its 2026 outlook is a stabilizing factor.

02

Market read

This is a company-specific leadership change with an immediate effective date, likely driving short-term sentiment and positioning around the diagnostics execution narrative.

03

What to watch

Traders may be over-weighting the interim label; the key near-term signal will be any subsequent permanent CEO appointment and updates on commercial diagnostics execution.

Relevance 6/10Novelty 6/10Timing: effective immediately, pre-market/early session reaction possible

Background

Everett Cunningham stepped down as President and CEO and a board member; Jim Gute, the Chief Commercial Officer, was appointed interim CEO while a successor search begins.

Company-level read

Ticker impact

$QTRXNeutralMedium confidence
Context

Quanterix CEO Everett Cunningham stepped down effective immediately, with Jim Gute named interim CEO while the board searches for a successor.

Expected impact

Likely modest volatility as investors assess management continuity, partially offset by the reaffirmed 2026 outlook.

Evidence & confidence

The article discloses an immediate CEO departure and interim appointment, which can affect sentiment and expectations, but provides no new financial guidance numbers beyond reaffirmation.

Market effects

May modestly affect sentiment toward diagnostics/clinical tools peers if investors extrapolate execution risk from leadership churn.

No clear regional spillover indicated in the text.

Primarily company-specific; no global macro or cross-border catalyst mentioned.

Counterpoint

The CEO change could be routine succession planning, and the reaffirmed 2026 outlook suggests management confidence, limiting downside.

Key entities

  • Quanterix Corporation

    Diagnostics company whose CEO transition and interim leadership appointment are disclosed.

  • Everett Cunningham

    Departing President and CEO, stepping down effective immediately.

  • Jim Gute

    Chief Commercial Officer appointed interim President and CEO.

Related articles

$QTRXMed

What Quanterix (QTRX) Said on Its Q3 Earnings Call

Quanterix (QTRX) reported a Q3 net loss of $21.6M, improved from last year. Adjusted EBITDA loss was $12.2M. Gross margin rose to 47.4%. LucentAD test volume doubled, but revenue from diagnostics fell to $1.2M. The company expects 2026 gross margin of 48-50% and $70M cash. Alzheimer's test discussions with FDA continue, with no clearance date given.

$QTRXMed

Quanterix Releases Financial Results for the Third Quarter of 2026

Quanterix Corp (QTRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Quanterix Releases Financial Results for the Third Quarter of 2026 Reports $35.0 million in revenue, up 6.3% sequentially, and $80.7 million of cash and marketable securities Initiatives to accelerate commercial effectiveness position the Company for growth in rest o

$QTRXHighAI 9/10

Quanterix (QTRX) Q2 2026 Earnings Call Transcript

Quanterix (QTRX) said Q2 2026 revenue was about $3 million (9%) below May guidance, citing broad-based shortfalls and commercial execution challenges. The company lowered 2026 revenue guidance to $142 million to $148 million from $169 million to $174 million and expects ~$80 million cash by year-end. Quanterix added commercial leaders (Jim Gute, Geoff Albrecht) and reorganized sales, citing Akoya integration savings of $85 million annually.

$QTRXMed

Quanterix Reshapes Sales Strategy, Targets Q4 FDA Decision for Alzheimer’s Blood Test

Quanterix (QTRX) said it completed Akoya Biosciences integration in Q2 and delivered $85M in revenue synergies. It is reshaping sales teams and expects clinical-trial bookings to rise QoQ. For its LucentAD Complete Alzheimer’s blood test, Quanterix filed a 510(k) in January and targets an FDA decision in Q4, possibly into Q1, citing a CMS price crosswalk of $897. It targets $10M diagnostics revenue in 2026.